There are an estimated 30

In 2006 for cystic fibrosis developRegeneRx Biopharmaceuticals announced today that it is seeking a strategic partner in the development of RGN-457 for the treatment of cystic fibrosis support. RGN-457 is based on thymosin beta 4 peptide as an inhaled therapy for these patients respond formulated . CF is a life-threatening genetic disease that affects the patient’s ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways of the lungs. There are an estimated 30,000 and 40,000 CF patients in the U.S. And Europe, be. It is therefore believed that. An orphan disease in both areas In 2006, the predicted median age of survival for people with cystic fibrosis 37 years ago. – Once in cystic fibrosis research and the development of some of CF therapies were currently participating in the market, I believe RGN-457 has the potential to be an important treatment option for CF Our published data indicate that T 4 is reduced. The cohesion of CF sputum, and data from other shows T? anti-inflammatory properties, strongly suggest that RGN-457 could a novel and important pulmonary therapy for people with CF, stated Bruce Rubin, Professor and Vice Chairman of Pediatrics, Wake Forest University, Winston-Salem, We have a significant amount in preclinical studies, which concluded for an IND application, in addition to existing toxicological and pharmacokinetic data from our current clinical programs, we believe RGN-457 could be developed relatively quickly with appropriate resources so that our interest is in identifying a strong strategic partner to work with us on this important product opportunity, said JJ Finkelstein, RegeneRx President & Chief Executive Officer.

About Cystic Fibrosis – is Cystic fibrosis is an inherited chronic disease of the lungs and the digestive system over 30,000 children and adults in the United States affected. Produce a defective gene and its protein product that the body is abnormally thick mucus, and leads to blockage in life-threatening lung infections. People with CF may salty-tasting skin, frequent cough and sputum; persistent infections of the lungs, shortness of breath, poor growth / weight gain and greasy, bulky stools or difficulty passing stools. About 1,000 new cases of cystic fibrosis are diagnosed each year. More than 70 percent of patients are diagnosed by age two. More than 40 percent of the CF patient population aged 18 or older. In 2006, the predicted median age of survival for 37 years.

However, not all the states support constraints federal funding for on embryonic research, which Times is reporting. Accordance with the former President George W. Bush in 2001 imposed the restrictions, finance were certain States action the allocation of funds and licensing of private Contribute embryonic stem cell. According to National Conference of State legislatures, California, Connecticut, IL, Maryland, Massachusetts, Los Angeles Times that New York City and Wisconsin all passed initiatives aimed pursue research on embryonic stem cell and Iowa and Missouri keep such research permissible but not to assign financial. Which Times reports that ‘generally supported ‘the Americans embryonic stem cell research and many are confident research result in treatments of spinal cord injuries, Parkinson’s disease and other disorders. According to a recent Gallup poll in February, conducted approximately 38 percent of Americans assist relaxation restrictions on federal funding of embryonic cells research and of an additional 14 percent preferred no limit. But, 41 percent of respondents said they prefer Bush’s restrictions on or removal financial support. Wolpe said: ‘On one hand people healing, that stem cell research want to brings , but they also want a law that recognizes the respect are have on embryos you want to will be is not only not only a raw material for academic research. ‘(Glanton, Los Angeles Times.